Glenmark Pharmaceuticals today said its novel chemical entity for potential treatment of chronic inflammatory disorders is entering human trials.
Glenmark has completed preclinical studies and Phase 1 enabling good laboratory practise for the molecule, GRC 27864, and has filed a Phase 1 application for first-in-human trial with the MHRA, UK, Glenmark Pharma said in a BSE filing.
The Phase 1 studies are to be initiated soon and are likely to get completed by January 2015, it added.
Glenmark Pharmaceuticals Ltd Chief Scientific Officer Michael Buschle said: "This is another first-in-class molecule and there is a significant unmet medical need. This announcement also reaffirms our position globally in the development of novel pain therapies."
Following human trial, Glenmark will initiate a proof of concept study in patients with acute pain.